INFECTIOUS DISEASE DIAGNOSTICS MARKET ANALYSIS

Infectious Disease Diagnostics Market, By Technique ( ELISA, Polymerase Chain Reaction (PCR),Immunoassays, Cell Cultures, Others),By Disease Indication (CNS Infection ,Meningitis, Brain Abscess), Diarrheal Disease ( Shigellosis, Cholera, Enteric/Typhoid Fever),Respiratory Infections(Tuberculosis, Influenza, Bronchitis),Blood Infections(Malaria, Dengue, Infectious Mononucleosis, Others),STDs(Chlamydia, Aids, Syphills, Others)),By End User (Hospitals, Diagnostic Centers, Clinics, Government Organizations), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Mar 2023
Code : CMI1971
Pages :167
Formats :
Excel and PDF
Industry : Clinical Diagnostic

Market Challenges And Opportunities

Global Infectious Disease Diagnostics market: Restraint

High price of molecular-based test kits is expected to hinder growth of the market. Molecular-based test kits plays a major part in the diagnosis of infectious disease. However, the high price of molecular test kits is leading to its low adoption, especially in US and Europe countries. Lack of reimbursement for certain infectious diseases is also expected to limit growth of the market. For instance, in July 2018, the Centers for Medicare & Medicaid Services significantly reduced the reimbursement for evaluation and management of complex cases, such as those suffering from infectious disease.

Global Infectious Disease Diagnostics Market: Opportunities

Introduction of cost-effective and reliable test kits is expected to offer lucrative growth opportunities to players in the market. Currently, very few effective diagnostic test kits are available for infectious diseases. Unavailability of effective diagnostic tools and high prices of existing test kits has triggered the need for cost-effective test kits with high- specificity and sensitivity.

Moreover, R&D in diagnostic kits is also expected to aid in growth of the market. For instance, in September 2019, researchers from University of Helsinki, Finland, reported that the antibody response against Puumala orthohanta virus can be measured at a high- sensitivity and specificity with the unorthodox point-of-care assay LFRET, a novel rapid assay for anti-tissue transglutaminase antibody detection, using urine as sample matrix.